ArticleClinical colorectal cancer2018
Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics.
Article in Clinical colorectal cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis.Journal of the National Cancer Institute · 2022Pooled it
- Association ofGenetics research · 2022Pooled it
- Prognostic role and clinicopathological features of SMAD4 gene mutation in colorectal cancer: a systematic review and meta-analysis.BMC gastroenterology · 2021Pooled it
- Clinicopathological Features of Right vs. Left Colorectal Carcinomas: Do the Differences Really Matter?Life (Basel, Switzerland) · 2026Article
- Radiologic and Pathologic Response as Predictors of Survival in Patients with Colorectal Peritoneal Metastases Undergoing Neoadjuvant Chemotherapy Followed by CRS-HIPEC: A Retrospective Study.Annals of surgical oncology · 2026Article
- Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types.Cancer research communications · 2025Article
- Differential response to immunotherapy in different lesions of MSI-H double primary colorectal cancer: a case report and literature review.AME case reports · 2025Article
- Comparative Outcomes of Neo-Adjuvant Chemo-Radiotherapy in Stage II and III Mucinous versus Non-Mucinous Rectal Adenocarcinoma: A Retrospective Study.Cancer management and research · 2025Article
- Clinicopathological characteristics and outcomes of colorectal mucinous adenocarcinoma: a retrospective analysis from China.Frontiers in oncology · 2024Article
- Primary Colorectal Tumor Displays Differential Genomic Expression Profiles Associated with Hepatic and Peritoneal Metastases.Cancers · 2023Article
- A GNAS Gene Mutation's Independent Expression in the Growth of Colorectal Cancer: A Systematic Review and Meta-Analysis.Cancers · 2022Review
- Pulmonary metastases from mucinous colorectal cancers and their appearance on CT: a case series.BJR case reports · 2022Article
- Correlation of Immunological and Histopathological Features with Gene Expression-Based Classifiers in Colon Cancer Patients.International journal of molecular sciences · 2022Article
- Molecular characterization of colorectal cancer related peritoneal metastatic disease.Nature communications · 2022Article
- Oncogene addiction to GNAS in GNASOncogene · 2022Article
- Development of a miRNA-based classifier for detection of colorectal cancer molecular subtypes.Molecular oncology · 2022Article
- Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer.The oncologist · 2022Article
- Biology and Clinical Implications of Fecal Occult Blood Test Screen-Detected Colorectal Cancer.JNCI cancer spectrum · 2022Article
- Mucinous adenocarcinoma: A unique clinicopathological subtype in colorectal cancer.World journal of gastrointestinal surgery · 2021Review
- Prognostic Factors for Post-Recurrence Survival in Stage II and III Colorectal Carcinoma Patients.Medicina (Kaunas, Lithuania) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe mucinous histologic subtype accounts for 5% to 20% of colorectal cancer (CRC) cases but remains poorly characterized. The present study characterized the baseline characteristics, mutational profile, and clinical outcomes of patients diagnosed with mucinous CRC. MATERIALS AND
methodsWe identified 1877 patients with metastatic CRC with available histologic findings and molecular profiling and summarized the baseline clinical and pathologic characteristics and overall survival (OS) stratified by the histologic type. The data from separate cohorts with consensus molecular subtype (CMS) and CpG island methylator information were also summarized.
resultsThe mucinous histologic type was found in 277 of the 1877 patients (14.8%) and was associated with an increased prevalence of microsatellite instability (P < .001) and a right-sided primary (P < .001). An increased frequency of CMS1 (microsatellite instability immune) and lower rates of CMS2 (canonical) were identified, with mucinous compared with nonmucinous adenocarcinoma (P < .0001). Mutations in SMAD4 (P < .001), GNAS (P < .001), ERBB2 (P = .02), BRAF (P < .001), and KRAS (P < .001) occurred at greater frequencies in the mucinous CRC cases, and TP53 (P < .001), APC (P < .001), and NRAS mutations (P = .03) were less common. Univariate (hazard ratio [HR], 1.38; 95% confidence interval [CI], 1.17-1.63; P < .001) and multivariate analysis (HR, 1.36; 95% CI, 1.12-1.64; P = .002) demonstrated that the mucinous histologic type is associated with worse OS. The features associated with the mucinous histologic subtype were independent predictors for shorter OS, including BRAF (HR, 1.74; 95% CI, 1.35-2.25; P < .001) and KRAS (HR, 1.42; 95% CI, 1.22-1.65; P < .001) mutations, right-sided location (HR, 1.20; 95% CI, 1.04-1.39; P = .01), and synchronous metastases (HR, 2.92; 95% CI, 2.49-3.42; P < .001).
conclusionCompared with nonmucinous adenocarcinoma, the mucinous histologic type is associated with a worse prognosis, even when controlling for known prognostic features. This unique biologic behavior should be considered in the treatment and prognostic assessment of patients with CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.